drugset / Trial / NCT05945368
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the pathology complete response rate (pathology Complete Response, pCR) of eribulin combined with trastuzumab + pertuzumab in neoadjuvant therapy for HER-2 positive early or locally advanced breast cancer.
Timeline
- Start
- 2022-02-25
- Primary completion
- 2024-02-25
- Completion
- 2025-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | 1.4 mg/m2 | — |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |